科前生物
(688526)
| 流通市值：83.95亿 | | | 总市值：83.95亿 |
| 流通股本：4.66亿 | | | 总股本：4.66亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 594,824,707.41 | 599,927,287.85 | 543,478,592.74 | 398,150,650.98 |
| 交易性金融资产 | 929,088,725.83 | 706,582,589.49 | 719,507,361.24 | 667,646,352.47 |
| 应收票据及应收账款 | 293,695,341.07 | 276,542,510.51 | 334,757,347.43 | 334,409,367.7 |
| 应收账款 | 293,695,341.07 | 276,542,510.51 | 334,757,347.43 | 334,409,367.7 |
| 应收款项融资 | 35,632,383.43 | 61,919,559.19 | 20,057,052.92 | 610 |
| 预付款项 | 6,209,078.43 | 5,862,029.47 | 2,856,407.34 | 4,340,687.65 |
| 其他应收款合计 | 4,523,561.63 | 4,702,103.75 | 4,871,442.77 | 4,822,722 |
| 存货 | 143,143,350.86 | 124,008,306.88 | 125,598,204.67 | 110,569,040.67 |
| 一年内到期的非流动资产 | 448,390,631.5 | 769,221,422.17 | 669,192,938.92 | 804,681,617.19 |
| 其他流动资产 | 32,653,068.5 | 32,427,957.38 | 52,758,667.05 | 71,949,048.43 |
| 流动资产合计 | 2,488,160,848.66 | 2,581,193,766.69 | 2,473,078,015.08 | 2,396,570,097.09 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 70,690,523.92 | 74,439,621.88 | 59,080,282.3 | 94,020,581.59 |
| 固定资产 | 688,787,581.13 | 711,114,114.92 | 734,739,719.35 | 736,142,700.86 |
| 在建工程 | 171,824,786.76 | 169,541,236.18 | 134,512,448.98 | 107,621,473.96 |
| 生产性生物资产 | 12,260,840.77 | 10,295,876.72 | 10,898,057.86 | 8,701,870.98 |
| 使用权资产 | 6,173,640.74 | 6,542,081.87 | 6,903,672.34 | 6,028,025.81 |
| 无形资产 | 65,086,970.09 | 64,106,199.88 | 65,103,156.95 | 59,567,614.02 |
| 商誉 | - | - | - | 3,307,452.36 |
| 长期待摊费用 | 1,358,296.49 | 1,458,483.2 | 1,595,396.66 | 1,212,679.99 |
| 递延所得税资产 | 670,211.68 | 1,215,536.87 | 959,239.68 | 189,357.67 |
| 其他非流动资产 | 1,070,325,581.3 | 1,019,647,560.45 | 1,008,951,926.86 | 1,018,602,996.42 |
| 非流动资产合计 | 2,087,178,432.88 | 2,058,360,711.97 | 2,022,743,900.98 | 2,035,394,753.66 |
| 资产总计 | 4,575,339,281.54 | 4,639,554,478.66 | 4,495,821,916.06 | 4,431,964,850.75 |
| 流动负债: | | | | |
| 短期借款 | - | - | - | 57,038,838.8 |
| 应付票据及应付账款 | 134,420,212.03 | 172,008,076.78 | 178,262,032.55 | 135,178,858.53 |
| 其中：应付票据 | 31,779,293.67 | 53,711,375.32 | 32,065,744.7 | 18,505,225.55 |
| 应付账款 | 102,640,918.36 | 118,296,701.46 | 146,196,287.85 | 116,673,632.98 |
| 合同负债 | 176,953,094.67 | 215,009,215.7 | 148,602,632.97 | 179,480,006.86 |
| 应付职工薪酬 | 36,296,774.93 | 27,409,293.53 | 53,904,867.7 | 41,058,984.46 |
| 应交税费 | 31,833,781.07 | 32,406,088.54 | 34,988,431.87 | 29,078,160.5 |
| 其他应付款合计 | 53,288,787.77 | 33,878,386.56 | 45,870,221.59 | 40,744,259.08 |
| 一年内到期的非流动负债 | 1,394,042.07 | 1,375,459.65 | 1,350,777.43 | 1,240,113.35 |
| 其他流动负债 | 1,127,479.59 | 2,703,942.57 | 519,184.89 | 1,460,766.89 |
| 流动负债合计 | 435,314,172.13 | 484,790,463.33 | 463,498,149 | 485,279,988.47 |
| 非流动负债: | | | | |
| 租赁负债 | 5,252,085.44 | 5,555,930.74 | 5,545,946.13 | 5,442,532.35 |
| 递延收益 | 61,814,120.16 | 64,070,703.02 | 66,040,575.43 | 67,507,699.7 |
| 递延所得税负债 | 17,932,488.81 | 20,047,205.75 | 17,714,034.54 | 15,062,730.22 |
| 非流动负债合计 | 84,998,694.41 | 89,673,839.51 | 89,300,556.1 | 88,012,962.27 |
| 负债合计 | 520,312,866.54 | 574,464,302.84 | 552,798,705.1 | 573,292,950.74 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 466,128,056 | 466,128,056 | 466,128,056 | 466,128,056 |
| 资本公积 | 1,125,023,249.08 | 1,140,131,280.73 | 1,140,131,280.73 | 1,140,131,360.65 |
| 减:库存股 | 17,692,584 | 35,841,765.86 | 34,766,002.37 | 31,670,006.58 |
| 其他综合收益 | 33,596,203.89 | -1,783,743.34 | -17,140,198.94 | 17,778,531.02 |
| 盈余公积 | 269,372,446.08 | 269,372,446.08 | 269,372,446.08 | 269,372,446.08 |
| 未分配利润 | 2,177,164,070.29 | 2,225,480,993.98 | 2,117,244,119.5 | 1,995,494,857.19 |
| 归属于母公司股东权益合计 | 4,053,591,441.34 | 4,063,487,267.59 | 3,940,969,701 | 3,857,235,244.36 |
| 少数股东权益 | 1,434,973.66 | 1,602,908.23 | 2,053,509.96 | 1,436,655.65 |
| 股东权益合计 | 4,055,026,415 | 4,065,090,175.82 | 3,943,023,210.96 | 3,858,671,900.01 |
| 负债和股东权益合计 | 4,575,339,281.54 | 4,639,554,478.66 | 4,495,821,916.06 | 4,431,964,850.75 |
| 公告日期 | 2025-08-26 | 2025-04-29 | 2025-04-29 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |